Cherenkov light production from the α-emitting decay chains of 223Ra, 212Pb, and 149Tb for Cherenkov Luminescence Imaging  by Wood, V. & Ackerman, N.L.
Contents lists available at ScienceDirect
Applied Radiation and Isotopes
journal homepage: www.elsevier.com/locate/apradiso
Cherenkov light production from the α-emitting decay chains of 223Ra,
212Pb, and 149Tb for Cherenkov Luminescence Imaging
V. Wood, N.L. Ackerman⁎
Department of Physics and Astronomy, Agnes Scott College, 141 E College Ave, Decatur, GA, 30030 United States






A B S T R A C T
Cherenkov Luminescence Imaging (CLI) is a new method to image radioactive therapeutic and diagnostic
agents, primarily in preclinical studies. This study used Geant4 and Python to generate the predicted Cherenkov
light production as a function of time for a set of isotopic chains of interest for targeted alpha therapy: 223Ra,
212Pb, and 149Tb. All are shown to produce substantial Cherenkov light, though time delays between initial
decays and the production of Cherenkov light requires caution in interpreting CLI.
1. Introduction
Researchers are increasingly using Cherenkov light in the study of
cancer treatment and imaging (Tanha et al., 2015). Many studies have
observed Cherenkov light in mice using black-box systems with cooled
CCD cameras, both for investigating positron emission tomography
(PET) imaging agents and tracking electron-emitting therapeutic
agents (Robertson et al., 2009; Xu et al., 2011). If the imaging or
therapeutic agent is located in shallow tissues, Cherenkov light can
even be detected in patients (Spinelli and Boschi, 2014; Thorek et al.,
2014).
Similar to PET, Cherenkov Luminescence Imaging (CLI) images
photons produced close to the decay site in order to infer the location of
the molecular agent to which the radioisotope is conjugated. In order
for a charged particle to produce Cherenkov light, it must have a speed
in excess of v=c/n, where c is the speed of light and n is the index of
refraction of the material. For electrons or positrons in water this
threshold corresponds to an energy of 263 keV. If an electron or
positron has an initial energy that exceeds the threshold energy, the
particle will produce Cherenkov light along its path until the energy of
the particle passes below the threshold. For positrons, the radius in
which Cherenkov photons are generated will be smaller than the
average distance at which the annihilation photons are produced
(Mitchell et al., 2011). Unlike PET, Cherenkov photons have a broad
spectrum in the optical and UV portion of the electromagnetic
spectrum, weighted towards the UV (Mitchell et al., 2011). This leads
to substantial scattering and absorption in tissue. Given speciﬁc tissue
optical properties and models of the radioisotope distribution, the
Cherenkov light ﬂuence can be estimated (Glaser et al., 2015). The
optical imaging of Cherenkov photons has many similarities to the
commonly-used techniques of bioluminescent and ﬂuorescent imaging,
and researchers have utilized 3D reconstruction algorithms, originally
developed for those techniques, in Cherenkov imaging (Hu et al.,
2012).
A number of α-emitting isotopes are of medical interest for targeted
alpha therapy (TAT). α particles have a number of beneﬁts, such as
high linear energy transfer and a short path length. Monoclonal
antibodies or other targeting vectors are conjugated to the α-emitting
radioisotope, frequently through a chelator like DOTA. (Baidoo et al.,
2013).
Unlike positrons and electrons, α particles from radioactive decay
do not have suﬃcient energy to directly produce Cherenkov light in
tissue, with a required energy over 1 GeV (Ackerman and Graves,
2012). However, many isotopes with medical applications have sub-
sequent decays that produce electrons with suﬃcient energy to create
Cherenkov light. If these daughter isotopes are spatially localized to the
original molecular agent, this Cherenkov light provides information on
the distribution of the radiopharmaceutical.
There can be substantial time delays if the Cherenkov-producing
daughters are further down the decay chain and there are isotopes with
longer half-lives. The initial decay typically breaks the chelations used
in the majority of TAT agents, such that the daughter isotope is no
longer bound at the site of interest (de Kruijﬀ et al., 2015). If the
daughter isotope is able to freely circulate and there is a substantial
time delay, the location of Cherenkov light production can have little
correlation with the original biological target of interest (Ackerman and
Graves, 2012).
If γ-rays are produced with suﬃcient energy, there is some
probability that the γ-rays will Compton scatter oﬀ electrons which
then can have suﬃcient energy to produce Cherenkov light. As the
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Compton-scattered electrons are not close to the original decay site,
this source of Cherenkov light will produce a diﬀuse background.
The Cherenkov production from certain α-emitting isotopes has
been previously studied through simulations and analytical modeling.
One study, by Gill et al., used Geant4 to simulate the radioactive decays
and the Frank-Tamm equation to predict the Cherenkov production.
They tabulated the total Cherenkov production for many isotopes up to
Z=92, including some α-emitters and their decay chains (Gill et al.,
2015). Another study focused on the decay chains of 225Ac, 211At, 213Bi,
212Bi, 230U and the corresponding Cherenkov production over time
(Ackerman and Graves, 2012). Beattie et al. (2012) used analytical
models and tabulated spectra to model the Cherenkov production
from225Ac and other nuclides. To our knowledge, the only α-emitter
that has been imaged via CLI is 225Ac, which has been imaged in mice
(Ruggiero et al., 2010; Pandya et al., 2016).
In this study we focused on 223Ra, 212Pb, and 149Tb. All three
isotopes have extended decay chains, shown in Fig. 1, with three or
more decays necessary to reach a stable state. The isotopes in the decay
chains have half-lives ranging from hundreds of nanoseconds to years.
Some decays produce Cherenkov photons directly via β− or β+
emission, while other decays and subsequent de-excitations create γ-
rays with suﬃcient energy to create Compton-scattered electrons with
energies above the Cherenkov threshold. While 223Ra was included in
the simulation study by Gill et al. (2015) we believe the other two have
not been previously evaluated.
These three isotopes in this study all have potential for TAT though
they vary in how close they are to widespread clinical use. 223Ra is used
in the commercial pharmaceutical Xoﬁgo and has been tested clinically
for bone metastasis (Parker et al., 2013). 212Pb has been studied in
clinical trials using trastuzumab as the targeting molecule (Meredith
et al., 2013). 149Tb, targeted via folate, was shown to be an eﬀective
treatment in mouse models (Müller et al., 2014) and another study
showed that TAT via 149Tb-labeled rituximab was eﬀective in a mouse
leukemia model (Beyer et al., 2004).
In this study, we used Monte Carlo simulations to understand how
Cherenkov production temporally relates to the activity and decay time
of the original isotope. The simulation data can be used to facilitate
analysis of CLI pre-clinical imaging for radiopharmaceuticals that
contain 223Ra, 212Pb, or 149Tb.
2. Methods
This study utilized two separate Monte Carlo simulations, sepa-
rately modeling the production of Cherenkov light from the radioactive
decay of single isotopes and simulating how a population of atoms
proceed through the decay chain.
2.1. Geant4 generation of Cherenkov production
Cherenkov photon production for individual isotopes was genera-
ted using the Geant4 toolkit (Agostinelli et al., 2003; Allison et al.,
2006), version 4.10.00. We constructed a modular physics list
from G4DecayPhysics, G4IonPhysics, G4RadioactiveDecayPhysics,
G4EMPenelopePhysics, and G4OpticalPhysics. In optical physics,
the Cherenkov process was speciﬁed with a maximum of 20 photons
per step, a maximum beta change per step of 10.0, and scintillation
was disabled. For radioactive decay, the half-life threshold was
set to 1 nanosecond, internal conversion was enabled, and atomic
Fig. 1. Decay chains for the studied isotopes with the thick borders denoting the starting points. Branching fractions of less than 0.1% are not shown.
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rearrangement was disabled. We enabled atomic de-excitation with the
ﬂuorescence and Auger processes.
We generated radioactive decays uniformly in cylindrical volumes
of water with a radius of 1.3 cm and a half-height of 0.5 cm, similar in
geometry to standard 6-well plates. The refractive index of water
between 400 nm and 700 nm was modeled with values taken from Hale
and Querry (1973).
Each isotope was isotropically distributed in the water volume for
10 runs of 100,000 decays each. Each isotope was simulated separately;
nuclear deexcitation of the daughters were included, but the ion track
was killed once the daughter nucleus reached the ground state. We
created a mean and standard deviation for Cherenkov photons
produced per decay of each isotope.
2.2. Monte Carlo modeling of time curves
In order to analyze how the population of atoms proceeds through
the decay chain, a simulation was developed implementing the Monte
Carlo approach for determining equilibrium ratios. The script is
programmed in the high-level, object oriented programming language
Python (van Rossum, 1995). A CSV ﬁle containing information on the
half-life and daughters of an isotope serves as the input and contains
information from the LBNL Nuclear Data Search (Chu et al., 1999).
We track a population of atoms, typically one million, by generating
the decays of each atom. After reading in the CSV ﬁle, the script
calculates the decay times and pathway for each atom using a random
number generator. The Cherenkov photon count for each decay is
calculated from a Gaussian distribution based on the mean and
standard deviation calculated from Geant4.
In addition to a global clock that tracks the population of atoms and
Cherenkov production as a function of time, we also recorded the time
between the initial decay of an individual atom and the production of
Cherenkov light. This separation time will be zero for Cherenkov
photons produced in the original (223Ra, 212Pb, 149Tb) decay, regard-
less of when that particular atom was calculated to decay.
To create plots, we created histograms of photons binned according
to time from the initial decay (separation time) and photons binned
according to the time since the start of the population. The y-axis was
normalized to represent the photon rate divided by the initial activity
(A0) of the sample in Becquerels.
3. Results and discussion
3.1. Cherenkov photon production rates
The rates of Cherenkov light production for individual isotope
decays are shown in Table 1. The values are reported as mean ± the
standard deviation, except for the cases in which no Cherenkov
photons were ever produced. As expected, the isotopes that decay via
emission of a high-energy electron have the highest rate of Cherenkov
production. The small number of Cherenkov photons produced by α-
emitting isotopes is due to high energy γ-rays Compton scattering and
producing energetic electrons that exceed the Cherenkov threshold.
As a comparative value, we also simulated the decay of 18F with the
same geometry and simulation parameters. This isotope had a
Cherenkov production of 1.18 ± 0.01 photons per decay. As all of these
photons are prompt with the decay of 18F to 18O, no time analysis is
needed.
These results are in agreement with past simulation studies. The
rate of Cherenkov photon production for 18F can be compared to the
results in both Gill et al. and Ackerman and Graves. Gill et al. reported
a production rate of 1.32 ± 0.01 while Ackerman and Graves reported
1.36 ± 0.01. Note that this second result is from a slightly diﬀerent
geometry that includes the plastic surrounding the liquid, which would
increase the photon production. The diﬀerence between the current
result and the result from Gill et al. is due to the diﬀerence in spectral
range. This current work, as well as Ackerman and Graves, uses 400–
700 nm, while Gill et al. uses 400–800 nm Using the spectral scaling
factor described in Gill et al. (2015), the Gill et al. results can be scaled
by a factor of 0.857 to be compared to our result of 1.18 ± 0.01 photons
per decay for 18F. Their scaled result is 1.13 photons per decay for 18F.
Gill et al. reported a total of 28 ± 0.1 photons per decay for the
223Ra decay chain, which would scale to 24 photons per decay for the
400–700 nm spectral range. Our total, calculated from summing the
values in Table 1 weighted by their branching fraction in the decay
chain, is 24.00 ± 0.08. While Gill et al. did not deﬁne the production of
photons from 212Pb, they deﬁned the production from 212Bi to be
31.4 ± 0.1 photons per decay, which scales to 26.9 photons per decay.
The corresponding Ackerman and Graves result for 212Bi is 30.5 ± 0.1
photons per decay, while here it is 27.3 ± 0.1 photons per decay.
Detected luminescence from tissue will depend upon source depth
and geometry, which is implementation-speciﬁc. We have not modeled
light propagation, including scattering and absorption, in order to keep
Table 1
The simulated Cherenkov production via Geant4 for the decay chains of interest. Values are reported as mean and standard deviation from 10 runs of 100000 events each.
Isotope Photons per Decay
223Ra 0.0093 ± 0.00042
219Rn 0.0049 ± 0.00040
215Po 0.000114 ± 0.000079
211Pb 10.96 ± 0.046
211Bi 0.0077 ± 0.00052
211Po 0.0058 ± 0.00093
207Tl 13.05 ± 0.062
212Pb 0.0500 ± 0.0012
212Bi 20.01 ± 0.092
212Po 0
208Tl 20.10 ± 0.08
149Tb 2.441 ± 0.038
145Eu 1.149 ± 0.031
149Gd 0.101 ± 0.0035
145Sm 0
149Eu 0.00171 ± 0.00042
145Pm 0
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our results general. Glaser et al. (2015) has shown that there is a linear
relationship between Cherenkov ﬂuence and photons per decay. The
above results can be compared to 18F, which has been widely imaged in
a number of animal models. Compared to 18F, the 212Pb chain will have
23 times the ﬂuence, 223Ra will have 20 times the ﬂuence, and 149Tb
will have 2.3 times the ﬂuence.
3.2. Time response of 223Ra
Fig. 2 shows the rate of Cherenkov photon production increases
until it reaches equilibrium in about 2 h. The rate of Cherenkov
production is 22.6 ± 0.3 photons per second per Becquerel of initial
223Ra activity, calculated in a window of 2–38 h.
The 223Ra chain has a substantial separation time between the
initial 223Ra decay and the production of Cherenkov light due to the
production of Cherenkov light primarily arising from the decays of
211Pb and 207Tl. As shown in Fig. 2, the peak occurs at 15 min. The
distribution has a tail into long times, so the average separation time is
almost 60 min.
The clinical uses of 223Ra are related to bone metastasis as radium
is naturally bone-seeking. The diﬀusion of the daughters is not a
signiﬁcant concern for therapy, as the α particles from 219Rn and 215Po
are expected within seconds of the initial 223Ra decay. Past work has
shown that less than 2% of the daughter nuclides migrate away from
the bones (Henriksen et al., 2003).
While the 223Ra decay chain produces signiﬁcant Cherenkov light, it
is primarily produced by the decays of 211Pb and 207Tl. Both of these
isotopes (and the intermediary 211Bi) have half-lives of many minutes,
creating a substantial delay between the initial 223Ra decay and the
production of Cherenkov photons. In the case that 223Ra and its
daughters are localized in bone, CLI will provide information on the
distribution of the therapeutic agent. Past studies utilized a gamma
camera to measure tissue activity from the characteristic γ-rays from
223Ra and 211Bi (Henriksen et al., 2003). CLI would enable in vivo
imaging, not possible for γ-spectroscopy.
3.3. Time response of 212Pb
The 212Pb decay chain produces substantial Cherenkov light, but it
primarily comes from the decays of 212Bi and 208Tl. As Fig. 3 shows, the
rate of production of Cherenkov light increases over an initial time
window as these daughter isotopes reach equilibrium with the 212Pb
generator. While the decay chain of 212Pb produces substantial
Cherenkov light, there is a signiﬁcant time separation between the
initial 212Pb decay and the creation of Cherenkov photons. The average
delay is 90 min.
While the Cherenkov light associated with this decay chain primar-
ily originates from the decay of 212Bi, that is also the isotope that has
primary therapeutic value in this chain. There is a need to assess the
distribution of 212Bi, which may disassociate from the chelation, when
testing TAT with 212Pb. A non-speciﬁc distribution of 212Bi can lead to
toxicity and healthy tissue damage (Kasten et al., 2016). Imaging has
proven to be a challenge for these isotopes, so CLI could prove useful in
directly assessing this therapeutic decay chain, rather than using
surrogate isotopes (Máthé et al., 2016).
3.4. Time response of 149Tb
Unlike the previous isotopes, the production of Cherenkov light
from 149Tb is initially maximum. The production rate decreases with
time as the activity present decreases. The production rate of
Cherenkov photons is smaller than the equilibrium rates of the other
isotopes, but is similar to that of 18F.
There are two distinct contributions to the separation time between
Fig. 2. (A) The Cherenkov production rate (in photons per second normalized by initial sample activity A0 in Becquerels) from
223Ra increases until equilibrium is reached, but for later
times the production decreases. (B) There is a wide distribution of time between the initial 223Ra decay and the production of Cherenkov photons. Probability is per minute.
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the initial 149Tb decay and the Cherenkov light production: a prompt
portion and a low level exponentially decaying over many days, as
shown in Fig. 4. While the prompt portion is much brighter, the long
time delay due to the 5.9 day half life of 145Eu may make certain types
of analysis impossible with CLI. If one wished to image the distribution
of a radiopharmaceutical shortly after injecting it into a mouse, CLI
would work. The contribution from the daughters, which may no longer
be chelated to the targeting molecule and freely circulating, will be
small compared to the Cherenkov light produced by 149Tb still in
circulation. However, after a few half-lives of 149Tb the directly
produced light would potentially be smaller than the light from the
decays of circulating daughters.
4. Conclusion
CLI could serve as a useful modality for the study of new radio-
pharmaceuticals containing 223Ra, 212Pb, and 149Tb. There is a delay
between the separation in time between the initial decay of the 223Ra
nucleus and the production of Cherenkov light, so the application of
CLI depends upon the target tissue. Past research has shown that when
223Ra is localized to bone surface, less than 2% of the 211Bi has left the
bone. For 212Pb, which primarily serves as a generator for 212Bi, the
isotope of primary therapeutic use also generates half of the Cherenkov
light. Analysis of 149Tb via CLI will be possible for times shortly after
injection, but after many hours the daughters will dominate the
Fig. 3. (A) The Cherenkov production rate (in photons per second normalized by initial sample activity A0 in Becquerels) from
212Pb increases during the ﬁrst two hours as the212Bi state
is populated. (B) There is a prompt component of Cherenkov production, but there is also a delayed component that peaks at 10 min. (C) The majority of the Cherenkov produced is an
hour or more after the initial 212Pb decay. Probability is per minute.
V. Wood, N.L. Ackerman Applied Radiation and Isotopes 118 (2016) 354–360
358
Cherenkov light production.
Researchers must use caution when interpreting CLI of radio-
pharmaceuticals utilizing 223Ra, 212Pb, and 149Tb. The speciﬁc design
of the radiopharmaceutical will determine whether or not the daugh-
ters will be localized to the original target location. Typical chelations
will be broken by the recoil energy from the decay, but liposomes and
other nanocarriers may be eﬀective at containing the daughters. If the
agent is up-taken into tumor cells, such as through biological targeting
from peptides or antibodies, the subsequent decays of the daughters
may occur within the cancer cell if the half-lives are short enough.
These factors are already considered in α-emitting therapeutic design
with a goal of minimizing the toxicity due to dose from circulating
daughters (Zalutsky and Pozzi, 2004). If daughters are largely localized
to the treatment location, CLI can be used to study these α-emitting
radiopharmaceuticals.
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